Skip to main content
. 2020 May 5;20:133. doi: 10.1186/s12876-020-01232-z

Fig. 2.

Fig. 2

Progression-free survival from initiation of 2 L treatment. a PFS with monotherapy, doublet therapy, triplet therapy, and overall; b PFS with taxane monotherapy, irinotecan monotherapy, fluoropyrimidine + irinotecan, and fluoropyrimidine + platinum